IPSC - Century Therapeutics Inc
NYSE * Health Care * Biotechnology
$2.59
+$0.22 (+9.28%)
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Key Statistics
Market Cap
$425.94M
P/B Ratio
2.58
EPS
$-0.15
Revenue Growth
-1.0%
Profit Margin
-0.1%
Employees
78
How IPSC Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
#6
of 6
Growth Rank
#6
of 6
Size Rank
#6
of 6
Century Therapeutics Inc Company Information
- Headquarters
- Pennsylvania; U.S.A
- Website
- www.centurytx.com
- Sector
- Health Care
- Industry
- Biotechnology